vs
Fortrea Holdings Inc.（FTRE）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
Fortrea Holdings Inc.的季度营收约是GRAIL, Inc.的15.2倍（$660.5M vs $43.6M）。Fortrea Holdings Inc.净利率更高（-4.9% vs -227.5%，领先222.6%）。GRAIL, Inc.同比增速更快（14.0% vs -5.2%）。Fortrea Holdings Inc.自由现金流更多（$121.6M vs $-63.9M）。过去两年GRAIL, Inc.的营收复合增速更高（27.7% vs -0.1%）
Fortrea Holdings Inc.是一家总部位于美国北卡罗来纳州达勒姆、注册地为特拉华州的合同研究组织，业务覆盖90个国家，主要服务制药、生物技术和医疗器械行业客户，为相关领域的研发提供专业支持。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
FTRE vs GRAL — 直观对比
营收规模更大
FTRE
是对方的15.2倍
$43.6M
营收增速更快
GRAL
高出19.2%
-5.2%
净利率更高
FTRE
高出222.6%
-227.5%
自由现金流更多
FTRE
多$185.5M
$-63.9M
两年增速更快
GRAL
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $660.5M | $43.6M |
| 净利润 | $-32.5M | $-99.2M |
| 毛利率 | — | — |
| 营业利润率 | -2.1% | -285.4% |
| 净利率 | -4.9% | -227.5% |
| 营收同比 | -5.2% | 14.0% |
| 净利润同比 | 46.9% | -2.2% |
| 每股收益（稀释后） | $-0.25 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTREGRAL
| Q4 25 | $660.5M | $43.6M | ||
| Q3 25 | $701.3M | $36.2M | ||
| Q2 25 | $710.3M | $35.5M | ||
| Q1 25 | $651.3M | $31.8M | ||
| Q4 24 | $697.0M | $38.3M | ||
| Q3 24 | $674.9M | $28.7M | ||
| Q2 24 | $662.4M | $32.0M | ||
| Q1 24 | $662.1M | $26.7M |
净利润FTREGRAL
| Q4 25 | $-32.5M | $-99.2M | ||
| Q3 25 | $-15.9M | $-89.0M | ||
| Q2 25 | $-374.9M | $-114.0M | ||
| Q1 25 | $-562.9M | $-106.2M | ||
| Q4 24 | $-61.2M | $-97.1M | ||
| Q3 24 | $-27.9M | $-125.7M | ||
| Q2 24 | $-138.4M | $-1.6B | ||
| Q1 24 | $-101.0M | $-218.9M |
营业利润率FTREGRAL
| Q4 25 | -2.1% | -285.4% | ||
| Q3 25 | -1.2% | -346.2% | ||
| Q2 25 | -46.5% | -446.9% | ||
| Q1 25 | -79.9% | -482.5% | ||
| Q4 24 | -8.0% | -358.0% | ||
| Q3 24 | -2.7% | -640.5% | ||
| Q2 24 | -7.7% | -5133.8% | ||
| Q1 24 | -5.6% | -851.1% |
净利率FTREGRAL
| Q4 25 | -4.9% | -227.5% | ||
| Q3 25 | -2.3% | -245.8% | ||
| Q2 25 | -52.8% | -320.7% | ||
| Q1 25 | -86.4% | -333.6% | ||
| Q4 24 | -8.8% | -253.8% | ||
| Q3 24 | -4.1% | -438.7% | ||
| Q2 24 | -20.9% | -4958.8% | ||
| Q1 24 | -15.3% | -819.3% |
每股收益（稀释后）FTREGRAL
| Q4 25 | $-0.25 | $-2.37 | ||
| Q3 25 | $-0.17 | $-2.46 | ||
| Q2 25 | $-4.14 | $-3.18 | ||
| Q1 25 | $-6.25 | $-3.10 | ||
| Q4 24 | $-0.68 | $-1.49 | ||
| Q3 24 | $-0.31 | $-3.94 | ||
| Q2 24 | $-1.55 | $-51.06 | ||
| Q1 24 | $-1.13 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.6M | $249.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $563.5M | $2.6B |
| 总资产 | $2.7B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTREGRAL
| Q4 25 | $174.6M | $249.7M | ||
| Q3 25 | $131.3M | $126.9M | ||
| Q2 25 | $81.2M | $127.4M | ||
| Q1 25 | $101.6M | $133.9M | ||
| Q4 24 | $118.5M | $214.2M | ||
| Q3 24 | $105.3M | $853.6M | ||
| Q2 24 | $126.2M | $958.8M | ||
| Q1 24 | $92.8M | $199.7M |
股东权益FTREGRAL
| Q4 25 | $563.5M | $2.6B | ||
| Q3 25 | $580.8M | $2.2B | ||
| Q2 25 | $589.2M | $2.3B | ||
| Q1 25 | $858.8M | $2.4B | ||
| Q4 24 | $1.4B | $2.5B | ||
| Q3 24 | $1.5B | $2.6B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.6B | — |
总资产FTREGRAL
| Q4 25 | $2.7B | $2.9B | ||
| Q3 25 | $2.7B | $2.6B | ||
| Q2 25 | $2.8B | $2.7B | ||
| Q1 25 | $3.1B | $2.8B | ||
| Q4 24 | $3.6B | $3.0B | ||
| Q3 24 | $3.7B | $3.1B | ||
| Q2 24 | $3.6B | $3.3B | ||
| Q1 24 | $4.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $129.1M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $121.6M | $-63.9M |
| 自由现金流率自由现金流/营收 | 18.4% | -146.5% |
| 资本支出强度资本支出/营收 | 1.1% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $88.3M | $-299.9M |
8季度趋势，按日历期对齐
经营现金流FTREGRAL
| Q4 25 | $129.1M | $-63.8M | ||
| Q3 25 | $86.8M | $-63.2M | ||
| Q2 25 | $21.8M | $-77.0M | ||
| Q1 25 | $-124.2M | $-95.0M | ||
| Q4 24 | $17.1M | — | ||
| Q3 24 | $-2.4M | $-104.6M | ||
| Q2 24 | $273.7M | $-171.8M | ||
| Q1 24 | $-25.6M | $-207.3M |
自由现金流FTREGRAL
| Q4 25 | $121.6M | $-63.9M | ||
| Q3 25 | $79.5M | $-63.6M | ||
| Q2 25 | $14.3M | $-77.3M | ||
| Q1 25 | $-127.1M | $-95.1M | ||
| Q4 24 | $13.9M | — | ||
| Q3 24 | $-10.6M | $-105.6M | ||
| Q2 24 | $262.5M | $-173.2M | ||
| Q1 24 | $-34.9M | $-209.8M |
自由现金流率FTREGRAL
| Q4 25 | 18.4% | -146.5% | ||
| Q3 25 | 11.3% | -175.8% | ||
| Q2 25 | 2.0% | -217.6% | ||
| Q1 25 | -19.5% | -298.6% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | -1.6% | -368.4% | ||
| Q2 24 | 39.6% | -541.7% | ||
| Q1 24 | -5.3% | -785.3% |
资本支出强度FTREGRAL
| Q4 25 | 1.1% | 0.2% | ||
| Q3 25 | 1.0% | 1.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 1.2% | 3.4% | ||
| Q2 24 | 1.7% | 4.3% | ||
| Q1 24 | 1.4% | 9.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTRE
暂无分部数据
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
